Related Experiment Videos
Synthesis of biologically active canine CCK-58.
Joseph R Reeve1, David A Keire, Tamer Coskun
1CURE Digestive Diseases Research Center, VAGLAHS, Los Angeles, CA 90073, USA. jreeve@ucla.edu
Regulatory Peptides
|April 11, 2003
Summary
Cholecystokinin-58 (CCK-58) and CCK-8 are biased agonists, meaning they activate the CCK-A receptor differently. This study synthesized CCK-58 to explore its unique physiological effects compared to CCK-8.
Area of Science:
- Gastroenterology
- Endocrinology
- Peptide Chemistry
Background:
- The carboxyl terminal octapeptide of cholecystokinin (CCK-8) is thought to mediate the bioactivity of all cholecystokinin (CCK) forms.
- The physiological role of CCK-58 remains unclear due to limited availability and purification challenges of natural CCK peptides.
Purpose of the Study:
- To synthesize canine-sulfated CCK-58 and investigate its distinct physiological actions compared to CCK-8.
- To examine the structural basis for differential bioactivity between CCK-58 and CCK-8.
Main Methods:
- Synthesis of canine-sulfated CCK-58 with preserved sulfation.
- Characterization of synthetic CCK-58 using amino acid analysis and mass spectrometry.
- Comparative analysis of pancreatic stimulation patterns induced by synthetic CCK-58 and CCK-8.
Main Results:
- Synthetic CCK-58 was structurally identical to natural CCK-58.
- Both CCK-58 and CCK-8 dose-dependently increased amylase release.
- Only CCK-58 stimulated bile-pancreatic output volume, indicating distinct physiological effects.
Conclusions:
- CCK-58 and CCK-8 act as biased agonists at the CCK-A receptor, mediating different biological responses.
- Differences in the solution conformations of CCK-58 and CCK-8 carboxyl termini likely explain their distinct biological activities.